Kitty Magic (DKT)
Combination IM sedation/anesthesia protocol for cats: dexmedetomidine (α₂ agonist), ketamine (dissociative / NMDA antagonist), and butorphanol or buprenorphine (opioid). Single IM injection; onset 5–10 min; reversible with atipamezole.
Clinical background
Kitty Magic, also called DKT after its three components, is a combination intramuscular injectable protocol for cats. A single injection of dexmedetomidine, ketamine, and an opioid (typically butorphanol or buprenorphine) provides reliable sedation and short-duration anesthesia in most healthy-to-mildly-compromised cats without requiring IV access. It is the feline equivalent of a “total IM induction” and is widely used for minor procedures, painful examinations, and pre-oxygenation before IV catheter placement.
Pharmacology
Dexmedetomidine is a selective α₂-adrenergic agonist. It produces dose-dependent sedation, analgesia, and muscle relaxation through presynaptic inhibition of norepinephrine release in the CNS. The vasoconstriction it causes produces a characteristic pale-to-grey mucous membrane appearance, this is expected and does not indicate poor perfusion in an otherwise stable cat. Bradycardia and a compensatory increase in systemic vascular resistance are the primary cardiovascular effects; cardiac output falls. Reversible with atipamezole.
Ketamine is a dissociative anesthetic and NMDA-receptor antagonist. At the doses used in DKT, it provides immobilization and somatic analgesia. It maintains pharyngeal-laryngeal reflexes better than most anesthetics, a clinical advantage for brief procedures, but does not abolish them. Increases salivation; glycopyrrolate or atropine is sometimes co-administered to reduce secretions, though most practitioners omit it at DKT doses. Ketamine is excreted unchanged by the kidneys in cats (unlike dogs and humans, where hepatic metabolism predominates), so renal impairment prolongs its duration significantly.
Butorphanol is a kappa-agonist/mu-antagonist opioid. In DKT it contributes to sedation (kappa agonism is sedating in cats), reduces the required doses of the other two components, and provides mild-to-moderate visceral analgesia. Duration is short (1–2 hours). Buprenorphine is a partial mu-agonist with a longer duration (4–6 hours) and superior somatic analgesia; it is preferred when post-procedure pain is anticipated.
Indications
- Minor surgical or diagnostic procedures in cats not requiring full inhalant anesthesia (laceration repair, radiographs, wound debridement, brief urethral obstruction relief, ear flush)
- Sedation for IV catheter placement in fractious or stressed cats
- Pre-oxygenation sedation before induction of inhalant anesthesia
- Field or transport sedation
DKT is not a substitute for full anesthetic monitoring. Even at standard doses, cats should be observed continuously and have oxygen supplementation available.
Dosing
Doses are weight-scaled per Plumb’s published table. Three sedation levels select the volume drawn of each component: Mild (sedation or premedication before anesthetic induction), Moderate (castration or minor surgical procedures), and Profound (invasive surgical procedures, including OHE and declawing). Butorphanol vs buprenorphine selection is based on expected pain duration, use buprenorphine when analgesia will be needed for more than 1–2 hours post-procedure.
All components are drawn into the same syringe and given as a single IM injection, typically into the epaxial muscles or semimembranosus/semitendinosus. Onset is 5–10 minutes; peak effect by 15 minutes.
Contraindications and cautions
- Cardiovascular disease: dexmedetomidine’s reduction in cardiac output is poorly tolerated in cats with HCM or other cardiomyopathy. Use with extreme caution or avoid; consider a low-dose protocol with echocardiographic guidance.
- Renal insufficiency: ketamine is renally cleared in cats; prolonged and unpredictable recovery in azotemic patients.
- Hepatic disease: dexmedetomidine is hepatically metabolized; impaired clearance in severe liver disease.
- Geriatric cats: reduce doses by 25–50%; duration is often longer than in young adults.
- Obese cats: dose on lean body weight; fat mass does not require additional sedation.
Reversal
Dexmedetomidine is reversible with atipamezole (same volume IM as dexmedetomidine given). Partial reversal can shorten recovery without fully waking the patient, useful if the cat is taking >45 minutes to recover normally.
Ketamine has no reversal agent. Butorphanol can be partially reversed with naloxone, but this is rarely necessary at DKT doses.
Drug interactions
- Other CNS depressants (additional opioids, benzodiazepines, acepromazine, inhalant anesthetics): additive sedation and respiratory depression. If transitioning to inhalant anesthesia after a DKT injection, reduce the inhalant MAC; cats can become profoundly anesthetized very quickly.
- Anticholinergics during the α₂-mediated bradycardia phase: atropine or glycopyrrolate given to “correct” the bradycardia of dexmedetomidine will raise heart rate against an already high systemic vascular resistance, increasing myocardial work and arrhythmia risk. Avoid unless bradycardia is hemodynamically significant (hypotension, weak pulses), in which case partial reversal with atipamezole is preferred.
- MAO inhibitors (selegiline, amitraz, linezolid): serotonin syndrome risk with the opioid component; avoid combination.
- Other α₂ agonists (xylazine, medetomidine): do not stack; cumulative cardiovascular depression is severe.
Sources
- Plumb’s Veterinary Drugs, dexmedetomidine, ketamine, and butorphanol monographs.
- Robertson SA, Lascelles BDX: Long-term pain in cats. J Feline Med Surg 2010.
- Ko JC et al: Comparison of anesthetic and cardiorespiratory effects of tiletamine-zolazepam-butorphanol and tiletamine-zolazepam-medetomidine in cats. JAVMA 1993.